Our ambition is to help make the UK one of the most pro-innovation health systems in the world.
We will do this by bringing decision-makers from across the health service together with innovators from industry to accelerate impactful and cost-effective products in a way that hasn’t happened before.
- For patients: this means access to new technologies and treatments faster than ever.
- For clinicians: you will have access to cutting-edge innovations that will help you deliver excellent care.
- For industry: we will help you understand the needs of patients and clinicians, and champion great solutions.
- For investors: innovations that meet NHS needs will receive greater support, from proof of concept to national commissioning.
Formed in response to the Accelerated Access Review published in October 2016, the AAC is chaired by Lord Ara Darzi and has members representing each of the collaborative’s key partner organisations, listed below.
A new unit has been set up in NHS England and NHS Improvement to support the AAC’s work to provide a more joined up approach, at all stages, to ensure the best, new innovations reach patients faster. This work includes horizon scanning for upcoming, cutting edge innovations that meet the needs of patients and the NHS, to providing support for providers to enable faster adoption and spread of already proven new treatments and diagnostic tools.
The AAC board meets three times a year and has the following responsibilities:
- Oversight of the AAC’s work programme.
- Selection of early stage categories of products (pre-NICE approval) and late-stage rapid uptake products (post-NICE approval) that will receive dedicated support from the AAC.
- Ensuring strategic alignment with programmes which impact on the health innovation ecosystem but sit outside the AAC’s direct responsibility.
The next meeting of the AAC Board is 4 March 2020.
Read the public minutes and papers from the board meetings below: